Invitrogen™ Briakinumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Product Code	Brand	Quantity
30282631	Invitrogen™ MA559519	100 μg
30284191	Invitrogen™ MA559520	1 mg

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. As of 2011 pharmaceutical development for psoriasis has been discontinued in the U. S. and Europe. Briakinumab targets and neutralizes interleukin-12 and interleukin-23.

Specifications

• Antigen: Briakinumab
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Classification: Recombinant Monoclonal
• Form: Lyophilized
• Isotype: IgG1
• Target Species: Human
• Gene Alias: ABT-874
• Product Type: Antibody

• Concentration: 1 mg/mL
• Applications: ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
• Conjugate: Unconjugated
• Host Species: Human
• Regulatory Status: RUO
• Formulation: 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
• Primary or Secondary: Primary
• Purification Method: Protein A